Novo's antibiotic fund participates in financing round of infectious diseases firm

Novo Holdings’s Repair Impact Fund, which finances early-stage antibiotic research, has participated in a million-dollar investment round of British biotech company Centauri, which is building a platform for the detection of new antibacterial candidates treating infectious diseases.
Photo: Novo Holdings / PR
Photo: Novo Holdings / PR

British biotech firm Centauri has secured USD 32m to advance its platform for antimicrobial resistance (AMR) research and development, which can identify and develop new antibacterial candidates designed to treat infectious diseases, Novo Holdings announces in a press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading